ALK and non-small cell lung carcinoma: In the PROFILE 1014 trial, which compared crizotinib with chemotherapy as first-line treatment for advanced ALK-positive NSCLC, the mPFS was significantly longer in patients who received crizotinib (10.9 months) compared to chemotherapy (7.0 months; HR, 0.45, 95% CI, 0.35–0.60; p < 0.001) [10].